AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03268057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX15/2503 + avelumab
Description: Dose escalation will begin at 5 mg/kg of VX15/2503 and will increase up to 20 mg/kg with a constant dose of avelumab at 10 mg/kg. A recommended phase II dose of VX15/2503 will be determined and then utilized in the expansion phase with 10 mg/kg of avelumab.
Study NCT04193137 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral sodium loading test,Seated saline infusion test and Captopril challenge test
Description: Oral sodium loading test : Patients received 6g oral sodium every day for 3 days.~Seated saline infusion test: All participants received the infusion of 2 liters of 0.9% saline over 4 h in seated posture.~Captopril challenge test: Patients received 50 mg captopril orally at 8-9 a.m. after sitting or standing for at least 2 h. Blood samples were drawn at time zero and 2 h after the challenge.
Study NCT00794300 — intervention group
Intervention type: DEVICE
Intervention: second magnetic resonance imaging scan
Study NCT01307254 — intervention group
Intervention type: PROCEDURE
Intervention: blood analysis
Description: A single venous blood test will be taken - 4 tubes (hematology, clotting, chemistry, sedimentation rate)
Study NCT03794219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Tape
Description: To all patients,750 mg/day oral naproxen is administered for 10 days. Additionally, in intervention group kinesio tape is applied 3 times a week for 2 weeks with a total of 6 sessions.
Study NCT03794219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral naproxen
Description: 750 mg/day oral naproxen is administered for 10 days.
Study NCT03794219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral naproxen
Description: 750 mg/day oral naproxen is administered for 10 days.
Study NCT01054859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avanafil
Description: 200 mg avanafil tablet QD plus 0.5 g/kg alcohol
Study NCT01054859 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: alcohol
Description: 0.5 g/kg alcohol
Study NCT01054859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: avanafil
Description: 200 mg avanafil tablet QD
Study NCT00773500 — intervention group
Intervention type: OTHER
Intervention: Electronic prescribing
Description: Implementation of a commercially available electronic prescribing system with clinical decision support
Study NCT03560271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclo-Z
Description: Cyclo (His-Pro) and zinc
Study NCT02345668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Protocol
Description: Emotion Regulation Protocol is an Internet-based Self-administered Protocol for emotional disorders, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in twelve modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.
Study NCT02345668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (Pharmacological Treatment)
Description: The Pharmacological Treatment provided by a psychiatrist in the mental health unit.
Study NCT02345668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (Psychological Treatment)
Description: The Psychological Treatment provided by a clinical psychologist in the mental health unit.
Study NCT01023087 — intervention group
Intervention type: DRUG
Intervention: Polymyxin E (Colistin)
Description: Antibiotic medication; dosage to be decided according to infectious disease consultant recommendation.
Study NCT01023087 — intervention group
Intervention type: DRUG
Intervention: Non-nephrotoxic antibiotics
Description: To be decided by the infectious disease consultant
Study NCT02426775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carglumic Acid
Description: Carglumic Acid 50 mg/kg/day (twice daily)
Study NCT00381784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Printed materials
Description: Role model stories comprise the heart of printed materials distributed throughout the target community. The role model stories are brief publications that depict personal accounts from individuals in the population of focus who have made or are planning to make a risk-reducing behavioral change. Depending on the population they are meant to reach and what behavior they are trying to influence, the stories may include examples of people who now carry condoms with them, talked to a partner about condom use, use condoms consistently, avoid sharing needles, or exhibited other risk reduction behaviors.
Study NCT00381784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer advocates
Description: Core Element 1 Core group of young gay men and additional volunteers recruited from the community. The core group and volunteers comprise the peer advocates who design and carry out all program activities.~Core Element 2 Designated space where most social events and meetings are held; also serves as a drop in center where young men can meet and socialize during specified hours.~Core Element 3 Social events to attract young gay men and to promote safer sex. Core Element 4 Teams of young gay men go to locations frequented by young gay men to discuss and promote safer sex, deliver appealing informational literature on HIV risk reduction and distribute condoms.~Core Element 5 Meetings of eight to 10 young gay men to discuss factors contributing to unsafe sex among men. Men practice safer sex negotiation and correct condom use skills.~Core Element 6 Publicity campaigns that attract men to the program by word of mouth and through articles and advertisements in gay newspapers.
Study NCT01943266 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein intake
Description: on the study day, the diet will be provided as free amino acids,with calories made up by a liquid diet and protein free cookies. Protein intake will be varied at 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8, and 2.0 g.kg/day
Study NCT03560271 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT00800319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDC-0313
Description: Oral solution given in 5, 15, 25, 50, and 75 mg single doses
Study NCT01646736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii Hook F
Description: Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
Study NCT01646736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 1.0 intravenous every month.
Study NCT04519125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)
Description: Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)
Study NCT04519125 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE)
Description: Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE)
Study NCT02518828 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High SpO2
Description: SpO2 range ≥96%
Study NCT02518828 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low SpO2
Description: SpO2 range 90-92%
Study NCT01646736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GC
Description: Prednisone or equivalent 1 mg/kg/d(up to 60 mg), gradually tapering to 7.5mg/d in 24 weeks.
Study NCT01646736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC
Description: Prednisone or equivalent 1 mg/kg/d(up to 60 mg), gradually tapering to 7.5mg/d in 24 weeks.
Study NCT02506972 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Classic Quaker Quick Oats
Description: Various doses of oats without or with sugar
Study NCT02506972 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cream of Rice Cereal
Description: Various doses of cereal without sugar
Study NCT04056676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block under ultrasound guidance
Description: Ultrasound-guided thoracic paravertebral blocks in T2, T4 level
Study NCT04056676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative modified PEC block
Description: Pectoral nerve block by surgeon under direct vision after total mastectomy
Study NCT04056676 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative modified PEC block
Description: Pectoral nerve block by surgeon under direct vision after total mastectomy
Study NCT04056676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GA with ETT
Description: General anesthesia with endotracheal intubation
Study NCT04056676 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GA with ETT
Description: General anesthesia with endotracheal intubation
Study NCT02633644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harmony System
Description: Percutaneous neuromodulation of the aortic wall
Study NCT03339960 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ergonomic measurement
Description: Ergonomic measurement of the surgeon and assistant
Study NCT00842712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide
Description: Cilengitide (Cil) will be administered at a dose of 1000 milligram (mg) as intravenous infusion twice weekly over 1 hour on Days 1 and 4.
Study NCT00842712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide
Description: Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1 and 4.
Study NCT00842712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m\^2) as intravenous infusion over 2 hours on Day 1.
Study NCT00842712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (Cis) will be administered at a dose of 75 mg/m\^2 as intravenous infusion on Day 1.
Study NCT03776760 — intervention group
Intervention type: DEVICE
Intervention: Fingerstick GeneXpert HCV RNA quantitative assay
Description: All participants at risk of HCV infection will receive HCV RNA testing using the GeneXpert finger-stick point-of-care HCV quantitative assay 6 monthly
Study NCT03776760 — intervention group
Intervention type: DRUG
Intervention: sofosbuvir/velpatesvir
Description: Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia
Study NCT03776760 — intervention group
Intervention type: DRUG
Intervention: glecaprevir/pibrentasvir
Description: Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia
Study NCT01420757 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: incisional hernia repair
Description: Tension-free open or laparoscopic incisional hernia repair
Study NCT02906137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral blood and intestinal biopsies will be collected
Description: Blood draw and intestinal biopsies
Study NCT02906137 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Peripheral blood and intestinal biopsies will be collected
Description: Blood draw and intestinal biopsies
Study NCT03735381 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer watch 'Xiomi mi band2'
Description: 1. They receive information on the use of the pedometer.~2. Carry the pedometer (Xiaomi Mi Band 2 ™) from 12 to 32GW.~3. Prescription of benefits of walking in pregnancy:~   * Receive information about the goal of steps / day to be reached: 10,000-11,000 steps / day (Only the intervention 2 group).~  * Receive information on the adequacy of walking with moderate intensity.~4. They will receive messages on the mobile phone remembering the goal to achieve and a notification that the researching staff will proceed to collect the average count of steps / day of the week prior to 20 and 32 gestation weeks (only for the intervention 2 group).
Study NCT03735381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pedometer watch 'Xiomi mi band2'
Description: 1. They receive information on the use of the pedometer.~2. Carry the pedometer (Xiaomi Mi Band 2 ™) from 12 to 32GW.~3. Prescription of benefits of walking in pregnancy:~   * Receive information about the goal of steps / day to be reached: 10,000-11,000 steps / day (Only the intervention 2 group).~  * Receive information on the adequacy of walking with moderate intensity.~4. They will receive messages on the mobile phone remembering the goal to achieve and a notification that the researching staff will proceed to collect the average count of steps / day of the week prior to 20 and 32 gestation weeks (only for the intervention 2 group).
Study NCT03673618 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Soluble Corn Fiber
Description: Fiber or placebo
Study NCT03673618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soluble Corn Fiber
Description: Fiber or placebo
Study NCT01708278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quercetin
Description: COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take one of the following for 1 week~1. Quercetin 500 mg/350 mg of vitamin C and 10 mg niacin~2. Quercetin 1000 mg/350 mg of vitamin C and 10 mg niacin~3. Quercetin 2000 mg/350 mg of vitamin C and 10 mg niacin
Study NCT01708278 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - sugar chew
Description: COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take placebo (sugar chew containing 350 mg of vitamin C and 10 mg niacin)
Study NCT00821288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survivorship Intervention
Description: Survivorship Consultation is a one hour consultation in a survivorship clinic. The consultation will be performed by a nurse practitioner under the supervision of a medical oncologist. The consultation will result in a detailed written document outlining the individuals Survivorship Prescription including treatment summary, surveillance recommendations, risk for late-effects, cancer screening recommendations, genetic risk, and life style recommendations. This written document will be provided to the patient and her treating physician. In addition, referrals will be made to appropriate adjunct services as needed (e.g. psychologist, nutritionist, social worker).
Study NCT03681808 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Contact Lens
Study NCT03681808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test
Description: Soft Contact Lens
Study NCT02161224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-4592
Description: Oral
Study NCT00800319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volume matched placebo; oral solution; single dose
Study NCT02046174 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RENCA macrobeads
Study NCT00928642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate by mouth
Description: imatinib mesylate - 400mg orally, daily on Days 1-5 and 8-12 of a 21 day cycle.
Study NCT02036164 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic radiation
Description: Radiation:~* Pelvic radiation 1.8 Gy/ day, 5 days/ week, 6 weeks~* Brachytherapy 30-35 Gy for 4-5 times
Study NCT02036164 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic radiation
Description: Radiation:~* Pelvic radiation 1.8 Gy/ day, 5 days/ week, 6 weeks~* Brachytherapy 30-35 Gy for 4-5 times
Study NCT02036164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 40 mg/m2 i.v.
Study NCT02036164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 40 mg/m2 i.v.
Study NCT02036164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175 mg m2 i.v.
Study NCT02036164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5 i.v.
Study NCT00716430 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality Improvement Programme
Description: Quality Improvement training programme
Study NCT01367704 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coaching Boys Into Men program
Description: Coaching Boys into Men (CBIM) program consists of a 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rationale for CBIM and the CBIM Coaches Kit. The Coaches use this CBIM toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth.
Study NCT01367704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching Boys Into Men program
Description: Coaching Boys into Men (CBIM) program consists of a 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rationale for CBIM and the CBIM Coaches Kit. The Coaches use this CBIM toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth.
Study NCT01244581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate
Description: Amoxicillin-clavulanate 40 mg/kg/day in two daily doses for 7 days
Study NCT01244581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin-clavulanate
Description: Amoxicillin-clavulanate 40 mg/kg/day in two daily doses for 7 days
Study NCT01244581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo mixture in two daily doses for 7 days
Study NCT03355560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480 mg IV infusion
Study NCT03606447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uproleselan
Description: \[14C\]-Uproleselan
Study NCT01460355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: injection of 5U in 0.1ml of saline solution will be given to the recessed muscle
Study NCT01460355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: injection of 0,1ml of saline solution will be given to the recessed muscle
Study NCT02793596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Obstetrical patients
Description: Epidural waveform analysis as a confirmation of loss of Resistance
Study NCT03535662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orvepitant
Description: Single oral dose
Study NCT03535662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Once daily dosing for 10 days
Study NCT04060381 — intervention group
Intervention type: DRUG
Intervention: Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamine
Description: Treatment/ intervention given according to standard protocols at the Neonatal Intensive Care Unit
Study NCT04806490 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: the diagnosis for Yin Deficiency Syndrome
Description: The measurement of the standard scale for syndrome differentiation of Yin Deficiency Syndrome
Study NCT01396265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: single dose
Study NCT01396265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: multiple doses
Study NCT04093765 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasensitive Rapid Diagnostic Test (URDT)
Description: Investigation will consist in 1 URDT.~For P. falciparum URDT positive:~* collection of 3x1cm dried blood spots on filter paper~* administration of a supervised antimalarial treatment course to individuals for which a P. falciparum will have been detected by URDT.~Specifically in group 1, a population list will be collected in each village prior to MSAT campaign and all participants will undergo:~* collection of a 200 µL-aliquot of capillary blood for each participant to the screening during the MSAT intervention.~* 1 URDT + collection of a 200µL-aliquot of capillary blood for each participant to the follow-up survey at M12.